{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rivaroxaban",
    "query": {
      "condition": "Rivaroxaban"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 85,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Rivaroxaban&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T11:39:40.573Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06961630",
      "title": "Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Myocardial Injury After Noncardiac Surgery"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2025-10-07",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06961630"
    },
    {
      "nct_id": "NCT01094886",
      "title": "Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis",
        "Osteoarthritis, Knee",
        "Osteoarthritis, Hip",
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ortho-McNeil Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-03",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-17",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Hollywood, Florida • Tamarac, Florida + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        },
        {
          "city": "Glen Cove",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01094886"
    },
    {
      "nct_id": "NCT00439777",
      "title": "Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin overlapping with and followed by VKA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4833,
      "start_date": "2007-03",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-27",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00439777"
    },
    {
      "nct_id": "NCT01747746",
      "title": "Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Thrombo-embolism",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin and Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-10",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-03",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01747746"
    },
    {
      "nct_id": "NCT02064439",
      "title": "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Thromboembolism",
        "Thrombosis",
        "Venous Thrombosis",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "BAY 59-7939",
          "type": "DRUG"
        },
        {
          "name": "ASA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3365,
      "start_date": "2014-03-05",
      "completion_date": "2016-11-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-19",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 24,
      "location_summary": "Beverly Hills, California • La Jolla, California • Ventura, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064439"
    },
    {
      "nct_id": "NCT03630055",
      "title": "Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Radial Artery Occlusion"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 15 MG Oral Tablet [Xarelto]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ottawa Heart Institute Research Corporation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 930,
      "start_date": "2018-10-03",
      "completion_date": "2025-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03630055"
    },
    {
      "nct_id": "NCT00571649",
      "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 8101,
      "start_date": "2007-12",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 121,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571649"
    },
    {
      "nct_id": "NCT02072668",
      "title": "The Effect of Rivaroxaban in Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Anemia",
        "Sickle Cell-Beta0-Thalassemia"
      ],
      "interventions": [
        {
          "name": "rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 14,
      "start_date": "2014-02",
      "completion_date": "2018-10-04",
      "has_results": true,
      "last_update_posted_date": "2020-04-13",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02072668"
    },
    {
      "nct_id": "NCT02690155",
      "title": "Real-world Comparative Effectiveness of Rivaroxaban Versus VKA",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "VKA (Vitamin K antagonist)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38831,
      "start_date": "2016-02-12",
      "completion_date": "2016-03-01",
      "has_results": false,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02690155"
    },
    {
      "nct_id": "NCT01684423",
      "title": "Oral Rivaroxaban in Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thrombosis"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Active comparator",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban (BAY59-7939) suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-02-19",
      "completion_date": "2016-09-01",
      "has_results": true,
      "last_update_posted_date": "2017-09-21",
      "last_synced_at": "2026-07-22T11:39:40.573Z",
      "location_count": 13,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01684423"
    }
  ]
}